AbbVie Sues Sun Pharmaceutical Over Generic Zemplar

Law360, Washington (January 25, 2013, 4:38 PM EST) -- Abbott Laboratories spinoff AbbVie Inc. hit Sun Pharmaceutical Industries Ltd. with a lawsuit in Delaware federal court on Friday, claiming the generic drugmaker is attempting to infringe on a patent for its kidney disease treatment Zemplar.

Sun told AbbVie on Dec. 10 that it had filed an abbreviated new drug application with the U.S. Food and Drug Administration to create 1-, 2- and 4-microgram formulations of generic paricalcitol capsules, which are used to treat secondary hyperparathyroidism, a common side effect of chronic kidney disease.

But AbbVie...
To view the full article, register now.